Prime MedicinePRME +2.09%25 Net Margin % is -5,738.55% as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Prime Medicine ranks worse than 89.65% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Prime Medicine's Net Income for the
three
months ended in Mar. 2026 was $-49.12 Mil. Prime Medicine's Revenue for the
three
months ended in Mar. 2026 was $0.86 Mil. Therefore, Prime Medicine's net margin for the quarter that ended in Mar. 2026 was -5,738.55%.
The historical rank and industry rank for Prime Medicine's Net Margin % or its related term are showing as below:
PRME'
s Net Margin % Range Over the Past 10 Years
Min: -6566.61 Med: -4342.44 Max: -65.45
Current: -4917.55
PRME's Net Margin % is ranked worse than 89.65% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs PRME: -4917.55
Prime Medicine (NAS:PRME) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Prime Medicine Net Margin % Related Terms
Prime Medicine Net Margin % Historical Data
* Premium members only.
The historical data trend for Prime Medicine's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prime Medicine's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's Net Margin % distribution charts can be found below:
* The bar in red indicates where Prime Medicine's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (PRME) has a Net Margin % of -5,738.55% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #849 out of 947 companies in the Biotechnology industry, placing it in the top 89.7%.
Is Prime Medicine's Net Margin % too high?
Prime Medicine's current Net Margin % is -5,738.55%. Based on the distribution chart, Prime Medicine ranks #849 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's Net Margin % compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #849 out of 947 companies for Net Margin %. This places Prime Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Prime Medicine and its competitors. Prime Medicine's current Net Margin % is -5,738.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current Net Margin % of -5,738.55%. The current Net Margin % is -5,738.55%. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Prime Medicine (PRME), the current Net Margin % is -5,738.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
